Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 25;16(3):e0249216. doi: 10.1371/journal.pone.0249216

Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia; health facility based cross-sectional study

Adugnaw Atnafu Atalay 1, Reta Kassa Abebe 2, Aberash Eifa Dadhi 3, Worku Ketema Bededa 4,*
Editor: Frank T Spradley5
PMCID: PMC7993874  PMID: 33765065

Abstract

Introduction

A pregnancy that has been complicated with Hepatitis B virus (HBV) infection results in typical management problems for both the mother and the newborn. One of the universal efforts in tackling the impact of chronic HBV is the prevention of mother-to-child transmission during Antenatal care via prompt screening as the majority of chronic infections globally harbored during this period. Rewarding result have been achieved in reducing this problem at this period of life through maternal screening programs and universal vaccination of infants. This study was aimed at assessing the seroprevalence and associated risk factor of HBV among pregnant women attending Antenatal Care (ANC) in Dilla University Referral Hospital (DURH), Southern Ethiopia.

Method

A facility- based cross- sectional study was conducted from December 01 to May 30, 2017 among pregnant women attending ANC. A total of 236 pregnant women were included in this study. All Pregnant women who were attending antenatal clinic and were volunteer during the study period were included, whereas those women who were unable to communicate due to any problem, and not volunteer to give informed consent were excluded. Volunteer participants were asked to complete a questionnaire and had offered to test for HBsAg infection. The data was analyzed using SPSS version 20 software. Logistic regression was used to determine the association between dependent and independent variables.

Results

From 215 pregnant women attending ANC, the prevalence of HBsAg by the rapid test was found to be 11 (5.1%). Among the study participants, 91.1% (215) were tested for HIV antibody during the ANC visit, with the positivity rate of 4.5%. The result showed 1.86% of the study participants who were tested for HIV were also positive for HBsAg. Among those factors affecting the transmission of HBV infection, multiple partners and HIV confection have significant association at P-value less than 0.05.

Conclusion

The Seropositivity of Hepatitis B Virus among Pregnant Women was found to be significant and hence, routine screening of pregnant mother at Antenatal care for this virus, and subsequent management according to the guideline for both the mother and child is recommended.

1. Introduction

Of all viral hepatitis, Hepatitis B Virus (HBV) is the most lethal virus. This virus is oncogenic and is one of the responsible viruses for Hepatocellular Carcinoma. Cirrhosis is another chronic complications of HBV [14]

It is 100 times more infectious than Human-Immuno-Virus with an incubation period of 6 weeks to 6 months [2, 5].

The vertical transmission of this virus from mother to child is among the common routes of transmission. The transmission is particularly significant in pregnant women with positive HBeAg, which is a surrogate marker of active replication, and hence infectivity. All the three possible contacts, namely during pregnancy, at the time of delivery, and postnatally while breastfeeding, are the potential times of transmission from infected mother to child [58]

HBV infection has both maternal and child complications. These include coagulation abnormalities, accentuation of Postpartum Hemorrhage, Renal failure, stillbirths, Neonatal death, Cirrhosis, and Liver Cancer. One of the successes in combating this virus is the invention of an effective vaccine against it. Hence, universal screening in antenatal visits and vaccinations is a priority for the early intervention and prevention of this deadly virus [6, 911].

Screening antenatal women for HBsAg can give an upright prevalence of the disease in a population. [7, 9, 12]. Global data showed that about 780 000 people die every year due to the harmful effects of hepatitis B virus [2, 13, 14]. About 8 to 8.2% of pregnant women in Ethiopia are supposed to be infected by this virus and the country is among the highly affected area by this virus [15, 16]

The recent studies that have done globally and locally still showed the moderate prevalence of HBV among pregnant mother as it has been evidenced by the studies done in Gambia, Ghana, Southern Ethiopia, and Northern Ethiopia with the Seropositivity rates of 9.2%, 7.7%,7.3%, and 9.2% respectively [1720].

The transmission during infancy and early Prevention of vertical transmission is an important area of universal efforts to reduce the burden of HBV as mother-to-child transmission is responsible for approximately one-half of chronic infections globally. “Although there are guidelines for universal infant HBV vaccination, rates of maternal HBV infection have increased annually by 5.5% since 1998” [10]. The risk of transmission is about 90 percent in those exposed at birth without vaccination, while the risk is about 20 to 30 percent in those exposed during childhood. Maternal screening programs and universal vaccination of infants have significantly reduced transmission rates [9, 11, 21, 22]. As far as our knowledge goes, there is an inadequacy of data regarding the prevalence of HBsAg among pregnant women in the study area and the study was aimed at assessing the burden of HBsAg among pregnant women with the view of alleviating the disease burden by providing universal screening and vaccination.

2. Material and method

2.1. Study area and period

After Institutional Review Board (IRB) of Dilla University had approved the ethical clearance, the study was conducted in DURH, Southern Ethiopia, altitude of the city ranges between 2000 and 2500 meters above sea level. DURH is found in Dilla Town, Gedeo zone SNNPR. It is located 360kms from Addis Ababa which is the capital city of Ethiopia and 90km from Hawassa which is capital city of SNNPR. Administratively Dill town is divided in to 3 Sub-cities (SC) and 8 Kebeles (K) and an estimated population size of 82,944. Out of these around 19,136 women are child bearing age group (15–49 years) and there are around 7,029 husband’s whose wives are pregnant and 6,487 husband’s having children below one years old. In the town there are 1 hospital, 2 health center, 33 private clinic, 6 health posts, 15 pharmacies and 28 Drug stores.

2.2. Study design and population

A facility based cross sectional study was conducted among pregnant women attending ANC in DURH, Southern Ethiopia. The source populations were all pregnant women attending ANC in DURH. All Pregnant women who were attending antenatal care clinics in DURH, Southern Ethiopia during the study period.

2.3. Eligibility

2.3.1. Inclusion criteria

All Pregnant women were attending antenatal clinic in the DURH during the study period and who were volunteering and give informed consent.

2.3.2. Exclusion criteria

Those women who were unable to communicate due to any problem.

2.4. Sample size

Sample was calculated by taking overall Hepatitis B infection prevalence among a cross-sectional study conducted among pregnant women in Gondar in 2008. Of 209 mothers included in the study, 11 (5.3%) 3.0% level of significance / margin of error [23]. This sample size will be estimated using the formula for calculating sample size for cross sectional study of estimation a single population proportion as described below.

n=(Zα/2)2P(1P)/(d)2=(1.96)20.053(10.053)/(0.03)2

214.3~214

The following assumptions were made during sample size calculation

Z = Standard deviation of the normal distribution = 1.96 (confidence level at 95%)

P = prevalence 5.3% (a cross-sectional study was conducted among pregnant women in Gondar in 2008. Of 209 mothers included in the study, 11 (5.3%) were found to be HBsAg positive.

100-P = pregnant women who not exposed

d = Tolerable error / level of significance = 3.0%.

X = 10% non-respondent rate = 21.43

Sample size = n (Minimum sample size) + X (non- respondent) Sample size (N) = 214 + 22 = 236. Sample size was 236.

2.5. Sampling procedure

Study subjects were selected by systematic sampling method by dividing the sample size by the number of pregnant women attending ANC two months before the study period. They were permitted to enter into the ANC clinic room for their routine follow up based on their turn of registration one by one. The aim of the study was briefed to the subjects, and they were asked for their willingness to be interviewed. Those who met the inclusion criteria and volunteer were included. Pregnant women who attended the ANC clinic for more than one time during the study period were excluded.

2.6. Study variables

2.6.1. Dependent variables

The prevalence of Hepatitis B surface Antigen, among pregnant women attending ANC in DURH, southern Ethiopia.

2.6.2. Independent variables

Socio demographic variables like;

  1. Maternal age

  2. Marital status,

  3. Occupational status

  4. Educational status

  5. Any surgical procedure

  6. Gestational age

  7. Body tattooing

  8. Genital mutilation

  9. History of blood transfusion

  10. History of multiple sexual practices

2.7. Ethical considerations

IRB of Dilla University had approved the ethical clearance. Based on the objective of the study an official letter was sent to Hawassa University Referral Hospital that was involved in the study from Dilla University, College of Health Science Research and Publication committee prior to the data collection period. Confidentiality was maintained and all respondents’ questionnaire anonymously prepared. Moreover, informed consent was employed to respondents by explaining the purpose of the study as well as maintaining subject’s confidentiality.

2.8. Data collection

The data for the study was derived from serological testing and questionnaires. Socio-demographic and associated factors data were collected using a standard structure questionnaire by professional Nurses after having received a clear explanation of the objective of the study and having signed the informed consent from the participants using a standard consent form designed for this study and interviewed using a questionnaire. Actual data (blood sample and questionnaire) were collected from December 01 to May 28; 2017.

2.9. Specimen collection and processing

After obtaining informed consent, 5 ml of venous blood was collected in plane tubes under aseptic conditions from peripheral vein by experienced laboratory personnel from all consenting pregnant women consecutively. These tubes was labeled with unique identification number and processed at the time of collection. The blood samples taken from the individuals were centrifuged at 3000 revolution per minute (RPM) for at least 20 minutes at room temperature and the serum was separated and tested.

2.10. Laboratory testing

All the serum samples were tested for HBsAg by using rapid test kit following standard operation procedure.

2.11. Quality assurance

The questionnaire was first prepared in English and translated back to Amharic then translated back to English to ensure consistency of the questions. Pre-testing of 5% the questionnaire, which was 12, was done prior to the study. The clarity, understandability and flow of each question and the time to fill the questionnaire was assessed. Daily all the collected data was checked for completeness by the principal investigator. All the data were double entered to ensure the data quality.

2.12. Quality control of serological test

Blood samples were collected aseptically from pregnant women and properly labeled by the patient identification number. The specimen was collected by the trained Laboratory personnel. The samples were centrifuged; the serum was separated appropriately and stored until transported to the laboratory.

2.13. Data analysis

SPSS version 20 software was used for data analysis. Logistic regression and 95% confidence intervals were calculated to assess the presence and degree of association between independent and outcome variables.

3. Results

3.1. Socio demographic characteristics

In this study a total of 215 pregnant women have participated with response rate of 91.1%. The mean age of the study participants was 24.76. The majority of study participants were primary school completed, 100 (26.5%), followed by secondary school completed 54 (25%). With regard to parity, majority were multiparous 192 (89.8%). In this study, most of the participants were attending ANC for their second gravidity 90(41.9%) and the remaining were great multipara 23 (10.2%). “Table 1

Table 1. Socio-demographic characteristics of pregnant women attending antenatal care at DURH from December to May 28, 2017.

Variable Option Total no%
Age in years 16–20 38(17.6%)
21–25 93(43.1%)
26–30 73(33.8%)
31-above 11(5.1%)
Educational status illiterate 45(20.8%)
Primary 100(46.3%)
Secondary 54(25.8%)
College 16(7.4%)
Occupation unemployed 9(4.2%)
House wife 142(65.07%
governmental 28(13%)
Private 35(16.7%)
Ethnicity Gedio 100(46.5%)
Wolyta 38(17.6%)
gurage 25(11.6%)
amhara 18(8.3%)
others 34(15.7%)
Religion protestant 148(68.5%)
orthodox 45(20.8%)
Muslim 20(9.3%)
Others 2(0.9%)

3.2. Prevalence of HBV infection

From a study conducted among pregnant women attending ANC in DURH, the prevalence of HBsAg by the rapid test was found to be 11 (5.1%). Regarding the age of the participants in the study, the most affected age group were age 26–30 7 out of 11 cases which were 63.3%. Gedeo ethnic group was the predominant (63.6%), and most of the participants were house-wife (81.8%). “S1 Table”.

3.3. Factors associated with the HBV infection

Factors associated with the prevalence of HBsAg were also determined by taking the proportion of HBsAg detection for the participants in the study.

Of the 215 pregnant women tested for HIV antibody, 10(4.5%) were positive out of which 4 (1.86%) of the study participants who were HIV positive were also positive to HBsAg. There was significant association between HIV infection status and HBV prevalence, at the P-value of 0.019.

Of the study participants, 26 (12.06%) had a history of multiple partners of which 7(3.26%) were positive for HBsAg. The majority of the participants in the study had genital mutilation, 61(28.3%), of which 6(2.7%) were positive for HBsAg. Tattooing was the second prevalence risk factor in study, 34(15.8%), of which 6(2.79%) were positive for HBsAg.

Among those factors affecting the transmission of HBV infection like age, marital status, gravidity, educational level, religion, and ethnicity none has a significant association. But factors like multiple partnership, genital mutilation, abortion history, HIV coinfection had significant association with binary logistic regression P value less than 0.2.

In this study, those who had Multiple partner were 17.03 times higher risk to be infected with HBV infection in relation with who had no history of multiple partner with the AOR 17.03 95% CI(4.570–63.537) at P-value 0.00 and those who had history of genital mutilation were 3.17 times at higher risk than who did not had history of genital mutilation with AOR 3.12 95% CI(0.093–1.07) at P-value 0.065. By the same token, tattooing had 7.543 times risks of acquiring the HBV with the AOR of 7.543(2.157–26.380) at the P-value of 0.002, abortion 3.56 times AOR 3.56 95 CI (1.023–12.147) at the P-value of 0.046 and HIV coinfection 18.762 times higher risks of being positive for HBsAg with the AOR 18.762 95% CI (4.302–81.822) at the P-value of 0.00 than their counterparts. “Table 2

Table 2. Seroprevalence and associated risk factors among pregnant women in DURH December-May 2017.

HBV Status
variable Option Total Negative Positive COR(95%CI) P value
Multipartener Yes 26(12.06%) 19(8.8%) 7(3.2%) 17.03(4.570–63.537) 0.00
No 189(87.9%) 185(91.2%) 4(1.86%)
Abortion Yes 11(5.11%) 8(3.7%) 3(1.39%) 3.56(1.023–12.147) 0.046
No 204(94.8%) 196(91.1%) 8(3.7%)
tattooing Yes 34(15.8%) 28(13.02%) 6(2.79%) 7.543(2.157–26.380) 0.002
No 181(84.1%) 176(81.8%) 5(2.3%)
Genital mutilation Yes 62(28.84%) 56(26.04%) 6(2.79%) 3.12(0.093–1.07) 0.065
No 153(71.1%) 148(68.843.7%) 5(2.3%)
HIV status Yes 10(4.6%) 4(1.86%) 6(2.7%) 18.762(4.302–81.822) 0.00
No 205(95.4%) 198(92.1%) 7(3.26%)

3.4. Multi variate analysis for selected factors associated with HBV infection

From this research conducted in DURH showed that five variables are associated with HBV infection by bivariate analysis from this factors only multiple partner and HIV coinfection had been independently associated with HBV infection. Multi partnership showed to be 9.910 times highly associated with HBV infection AOR 9.910 95% CI(1.852–53.103) P-value 0.007. HIV coinfection had been also independently associated with HBV infection, the data showed it was 18.762 times higher in the risk of developing HBV infection AOR 18.762 95% (1.253–55.928) at P-value of 0.030. “Table 3

Table 3. Multi variate analysis for selected factors associated with HBV infection, DURH December-May 2017.

Variable Positive Negative AOR(95%CI) P-VALUE
Multi partners 7(3.2%) 19(8.8%) 9.910(1.852–53.103) 0.007
HIV Status 6(2.7%) 4(1.86%) 18.762(1.253–55.928) 0.030

4. Discussion

In this study, the prevalence of Seropositivity for Hep B virus was found to be 5.1%, which was higher than research conducted in the United States to determine the seroprevalence of hepatitis B surface antigen in pregnant women. In the study conducted in the USA the HBsAg prevalence among white non-Hispanics was 0.60%, black non-Hispanics 0.97%, Hispanics 0.14%, and Asians 5.79% [24], but also much higher than another study conducted in India in 2016, which was 1.01% [25].

The Seropositivity rate in this study is lower than the recent studies done in Gambia, Ghana, and Southern and Northern parties of Ethiopia, which were 9.2%, 7.7%, 7.3%, and 9.2% respectively (17–20). This is evidenced by the recent publication on the Journal of American Medical Association (JAMA), which highlights the persistent increments of HBV Seropositivity despite the availability of policy and guidelines in screening and vaccinating as per the guideline [10]. This will be a huge assignment for all the stakeholders working toward the control of this virus.

In this study, most of the participants were in the second gravidity 90(41.9%) which was comparable to research conducted in the United States [24, 26].

This disparity might be because of differences in sampling procedures, geographical location government attention level for the infection, Health seeking behaviors of the pregnant mother, Cultural practices, and socioeconomic level differences that need to be justified by further studies.

In this study prevalence of HBV infection, 5.1%, was almost comparable to a similar study conducted in Gondar (5.3%). The most commonly affected age group was age 26–30 in our study which is different from the study conducted in Gondar 16–28 [23].

In this study, the prevalence of HBV infection, 5.1%, was higher than a study conducted in Arbaminch hospital (4.3%). Commonly affected age group were comparable in the two studies in our 26–30 and Arbaminch hospital up of 25–29 years. In this study multi-partners, and HIV status had significant association but in Arbaminch hospital, none of the Sociodemographic factors were significantly associated with HBsAg Seropositivity [27, 28].

The leading risk factors for the acquisition of the virus in this study were genital mutilation 61(28.3%) followed by tattooing 34(15.8%) but it was sharp material in Debra-Tabor hospital, Gondar (93.3%) [23]. This could be the cultural differences between the two areas.

In this study, HIV co-infection and multiple partners had been independently associated with HBV infection, AOR 9.910 95% CI (1.852–53.103) p-value 0.007 and HIV co-infection AOR 18.762 95% CI (1.253–55.928) respectively. This is almost comparable with the studies done in other areas and heralds the due attention needed to tackle this virus in the aforementioned groups of patients [23, 27, 28]. This needs to be verified by further studies. As most of the deliveries are home delivery, the likelihood of being exposed to HBV increases. HIV and HBV share the same mechanisms for transmission and their co-occurrence might tell us these. The negative health outcomes of these dual infections further fuel chronicity and complications [2933]. These findings need to be verified by further studies for evidence-based interventions.

5. Conclusion

This study revealed the prevalence of Seropositivity for Hep B virus by the rapid test was an intermediate prevalence according to the WHO classification, which was found to be 5.1%. So routine screening of pregnant mother for HBsAg during ANC follow up and prompt vaccination of the exposed newborn is recommended.

Supporting information

S1 Questionnaire

(PDF)

S1 Table. Seroprevalence of HBsAg among pregnant women attending ANC in DURH from December to May 28, 2017.

(PDF)

Acknowledgments

The authors acknowledge all the respondents who took part in the study.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

This study was funded by the Ministry of Science and Higher Education and supervision of Dilla University College of Medicine and Health Sciences. The funding organization has no role in the design of study and data collection, analysis, interpretation of the results and preparation of manuscript.

References

  • 1.N. G (2014) Hepatitis B diagnosis, prevention and treatment. Clinical Chemistry 43: 1504. [PubMed] [Google Scholar]
  • 2.WHO (2014) http://www.who.int/mediacentre/factsheets/fs204/en/index.html, Hepatitis B Fact sheet.
  • 3.Kolawole O W AaOA (2012) Seroprevalence of hepatitis B surface antigenemia and its effects on hematological parameters in pregnant women in Osogbo, Nigeria. Virology Journal 9: 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mohammed Seid B.G. AA (2014) Sero-prevalence of HBV and HCV Infections Among Pregnant Women Attending Antenatal Care Clinic at Dessie Referral Hospital, Ethiopia. 2014. ADVANCES IN LIFE SCIENCES AND HEALTH 1.
  • 5.Olokoba AB S F, Danburam A, Olokoba LB, Midala JK, and Badung L, et al. (2011) Hepatitis Virus infection amongst pregnant women in North-Eastern Nigeria—A call for Action. Nigerian Journal of Clinical Practice 14: 10–13. 10.4103/1119-3077.79232 [DOI] [PubMed] [Google Scholar]
  • 6.Umare A S B, Gobena T, Mariyam Haile (2016) Hepatitis B Virus Infections and Associated-Factors among Pregnant Women AttendingAntenatal Care Clinic at Deder Hospital, Eastern Ethiopia. PLOS ONE 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dwivedi M M P, Misra V, Pandey A, Pant S, Singh R et al. (2011) Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol 30: 66–71. 10.1007/s12664-011-0083-y [DOI] [PubMed] [Google Scholar]
  • 8.WHO Hepatitis B and breastfeeding. 1996. http://www.who.int/maternal_child_adolescent/documents/pdfs/hepatitis_b_and_breastfeeding.pdf. Accessed May 9, 2020.
  • 9.Shukla S M G, Jais M, & Singh A., (2011) A Prospective Study on Acute Viral Hepatitis in Pregnancy; Seroprevalence, and Fetomaternal Outcome of 100 cases. Journal of Bio science and Technology 2: 279–286. [Google Scholar]
  • 10.Association AM (2019) JAMA | Screening for Hepatitis B Virus Infection in PregnantWomen 2019; 322 (4) page 1 JAMA 322: 1. [Google Scholar]
  • 11.Lem EA. K P (2016.) Assessing Prevalence and Risk Factors of Hepatitis B Surface Antigen amongst Pregnant Women Attending Antenatal Clinic in the Northwest Region of Cameroon. European Journal of Research in Medical Sciences, 4. [Google Scholar]
  • 12.Ahizechukwu C U AaCO (2011) Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virology Journal: 8–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mahamat A L D, and Djossou F. Am J Trop Med Hyg (2010) High Prevalence of HBsAg during Pregnancy in Asian Communities at Cayenne Hospital, French Guiana. Am J Trop Med Hyg 83: 7011–7013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.S. R.a, S. J.S. (2013) Hepatitis B Vaccination in Pregnancy in the United States. 1: 167–173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.C.H.B.I.i.P.W.E (2007) Chronic Hepatitis B Infection in Pregnant Women. Epidemiology update 2007.: 3–4.
  • 16.Health FMo (August 2015) National Expanded Program on Immunization. 2: 2–3. [Google Scholar]
  • 17.Bittaye Mustapha I P, Ekele Bissallah Ahmed, Obed Samuel Amenyi and Nyan Ousman (2019) Hepatitis B virus sero-prevalence amongstpregnant women in the Gambia. BMC Infectious Disease 19. 10.1186/s12879-019-3883-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dortey Benjamin Ansah A EA, Lassey A. T., Damale N. K. R., Maya Ernest T. (2019) Seroprevalence of Hepatitis B virus infection and associated factors among pregnant women at Korle-Bu Teaching Hospital, Ghana. 15: 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bancha Belete K AA, Chanko Kebreab Paulos, Workie Shimelash Bitew, Tadese Takele (2019) Prevalence of hepatitis B viruses and associated factors among pregnant women attending antenatal clinics in public hospitals of Wolaita Zone, South Ethiopia. 15: 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gebremedhin KB K H S EG (2019) Prevalence of Hepatitis B Virus Infection and Factors Associated with Hepatitis B Virus Infection Among Pregnant Women Presented to Antenatal Care Clinics at Adigrat General Hospital in Northern Ethiopia Dove press International Journal of Women’s Health 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yohanes T. Z Z, Chufamo N. (2016) Seroprevalence and Predictors of Hepatitis B Virus Infection among Pregnant Women Attending Routine Antenatal Care in Arba Minch Hospital, South Ethiopia. Hindawi Publishing Corporation Hepatitis Research and Treatment,: 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.U Bt. (2013) Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern Nigeria. African Health Sciences 13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Walle F A D, Alem A, Tadesse E and Desta K. (2008) Prevalence of hepatitis B surface antigen among pregnant women attending antenatal care service at Debre-Tabor hospital, Gonder, Ethiopia. Ethiopia JHealth Sci 17: 13–17. [Google Scholar]
  • 24.Gary L Euler KGW, Andrew L Baughman, Walter W Willimas (2003) Hepatitis B surface antigen prevalence among pregnant women in urban areas: Implications for testing, reporting, and preventing perinatal transmission [PubMed]
  • 25.Sathiyakala Rajendiran UG, Karthika Jayakumar Seroprevalence of Hepatitis B infection among pregnant women in South India.
  • 26.W.H.O (2013) Department of communicable diseases surveillance and response.
  • 27.al TYe (2015:) Seroprevalence and Predictors of Hepatitis B Virus Infection among Pregnant Women Attending Routine Antenatal Care in Arba Minch Hospital, South Ethiopia.: 1–7. [DOI] [PMC free article] [PubMed]
  • 28.Sisay kibray et al. (2014:) Seroprevalence of HBsAg among pregnant woman and rate of vertical transmission in 3 teaching hospitals in Addis Ababa, Ethiopia: 38–40. [Google Scholar]
  • 29.Weber R S C, Friis-Møller N, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. 166(15):1632–41. Arch Intern Med 166: 1633–1640. [DOI] [PubMed] [Google Scholar]
  • 30.WHO (2021) More about HIV and HBC Coinfection.
  • 31.NIH (2020) HIV and Hepatitis B Last Reviewed: September 24, 2020
  • 32.Gatanaga H Y A, Kikuchi Y, et al. (2000) Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 19: 237–239. 10.1007/s100960050468 [DOI] [PubMed] [Google Scholar]
  • 33.Thio CL S E, Skolasky R, et al. (2002) Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet 360: 1924. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Frank T Spradley

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

13 Jan 2021

PONE-D-20-36836

SEROPOSITIVITY OF HEPATITIS B VIRUS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN DILL UNIVERSITY REFERRAL HOSPITAL ,2017; Health facility based Cross-sectional Study

PLOS ONE

Dear Dr. Bededa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 18 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.  If the original language is written in non-Latin characters, for example Amharic, Chinese, or Korean, please use a file format that ensures these characters are visible.

3. Please state whether you validated the questionnaire prior to testing on study participants. Please provide details regarding the validation group within the methods section.

4. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as:   

-    a description of any inclusion/exclusion criteria that were applied to participant recruitment,

-    a table of relevant demographic details,

-    a statement as to whether your sample can be considered representative of a larger population,

-    a description of how participants were recruited, and

-       descriptions of where participants were recruited and where the research took place.

5. For more information on PLOS ONE's expectations for statistical reporting, please see https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting. Please update your Methods and Results sections accordingly.

6. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files

7. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting study aimed at assessing the seroprevalence and associated risk factor of HBV among pregnant women attending Antenatal Care (ANC) in Dilla University Referral Hospital (DURH), Southern Ethiopia. There are a number of issues in the paper.

Abstract:

Methods: The authors should include the inclusion and exclusion criteria in the abstract. What were the outcome measures?

The authors wrote: 215 study participates were tested for HIV antibody, of which 10 (4.5%) were turned

to be positive for HIV. The authors should avoid starting a sentence with figures.

The authors stated: The Seropositivity of Hepatitis B Virus among Pregnant Women was found to be significant. Why did they say that the study is significant? How did they arrive at significant?

iNTRODUCTION

It is well written.

The authors should beef up the justification for the study.

Results and Discussion are ok.

Reviewer #2: The manuscript entitled: "SEROPOSITIVITY OF HEPATITIS B VIRUS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN DILL UNIVERSITY REFERRAL HOSPITAL ,2017" is a facility based cross-sectional study that aimed to assess the seroprevalence of HBV among pregnant women attending antenatal care in DURH as well as the risk factors associated with HBV infection in this population. Overall, this study presents the results of original scientific research that addresses an interesting question and was designed appropriately to achieve the two aforementioned aims. However, the manuscript presents certain issues and requires substantial revision in order to be published. Firstly, in the Introduction, the authors should clearly summarize the state of research in the field by citing more recent seroplevalence studies, globally. Since the author's goal is to underline the need for global screening and vaccination during pregnancy, they should consider reading and citing the latest guidelines from WHO, EASL, or AASLD, like the article: "US Preventive Services Task Force; Douglas K Owens et al. Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement, JAMA. 2019 Jul 23;322(4):349-354." In the Materials and Methods, the sample size calculation procedure is not easy to read and understand, therefore it should be elucidated. One major issue is the Results section of the manuscript, as the results are not clearly presented, some values are missing and some values are different for the ones in the Tables. Overall, the authors should pay the attention to rephrase the results in an appropriate manner. A Table summarizing the sociodemographic characteristics should also be added, while the other Tables could also be restructured. Overall, the discussion is interesting, as it compares the results with previous data from the same country and two studies conducted in the USA and in India. However, the authors should cite the original studies from these two countries and enrich the discussion with more recent publications. Finally, since the authors' mother tongue is not English, they should carefully revise the manuscript for grammatical and syntactical errors.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: George Eleje

Reviewer #2: Yes: Nikoletta Maria Tagkou

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 25;16(3):e0249216. doi: 10.1371/journal.pone.0249216.r002

Author response to Decision Letter 0


12 Feb 2021

Manuscript PONE-D-20-36836

Point- by- Point Rebuttal Letter

We really thank the editor and the two reviewers for their valuable comments on our manuscript.

Please kindly find below our response to each point raised by the academic editor and reviewers. We hope that we clearly addressed all of them, and that the manuscript will be now suited for publication. We bolded the comments, and highlighted the responses by water blue color.

Sincerely,

On behalf of all the four authors,

Worku Ketema Bededa

Academic editor:

Journal requirements

1. Plos one templates

� We have checked the templates and made the adjustments to meet the journal requirements.

2. Additional information regarding survey or questionnaire-

� We put the questionnaire in the supplementary data in both Amharic and English and please kindly see the supplementary documents.

3. State whether you validated the questionnaire prior to testing on the study participants. Please provide details regarding the validation groups within the method section

� Thank you for your comments; The questionnaire was first prepared in English and translated back to Amharic then translated back to English to ensure consistency of the questions. Pre-testing was done on 12 pregnant mother prior to the study (5 % of the total sample size, which was 236). The clarity, understandability and flow of each question and the time to fill the questionnaire were assessed with a bit modification of the questionnaire. All the collected data was checked for completeness by the principal investigator daily. All the data were double entered to ensure the data quality

4. In your methods; Please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analysis such as;

-A description of any inclusion/exclusion criteria that were applied to participant recruitment

-A table of relevant demographic details

-A statement as to whether your sample can be considered as representative of a large population

- Description of how participants were recruited, and

-Description of where participants were recruited and where the research took place

Response; We are grateful to respond to your constructive comments, and here are the responses one by one

� Regarding the Eligibility criteria

Inclusion Criteria

All Pregnant women were attending antenatal clinic in the DURH during the study period and who were volunteering and give informed consent

Exclusion Criteria

Those women who were unable to communicate due to any problem

� The table of relevant demographic details has been incorporated in the main manuscript(Table 1)

� One of the limitations of this paper is small sample size( due to financial constraint by the time of the study), and I admit that the finding will not be an exact representative of large population, but will only give as an insight on the burden of the virus and associated factors. It will pave a path for the future study that will be done with better sample size.

� Participant recruitment has been elaborated under the sampling procedure. Participants were recruited from the ANC clinic of Dilla University Referral Hospital, Dilla, Ethiopia

Sampling procedure

� We appreciate for your review, and here is the response for this specific comment; Study subjects were selected by systematic sampling method by dividing the sample size by the number of pregnant women attending ANC two months before the study period. They were permitted to enter into the ANC clinic room for their routine follow up based on their turn of registration one by one. The aim of the study was briefed to the subjects, and they were asked for their willingness to be interviewed. Those who met the inclusion criteria and volunteer were included. Pregnant women who attended the ANC clinic for more than one time during the study period were excluded.

Study variables-We are sorry for not to incorporate this in the original manuscript initially,and here are the edited one;

Dependent variables

� The prevalence of Hepatitis B surface Antigen, among pregnant women attending ANC in DURH, southern Ethiopia

Independent variables

� Socio demographic variables like;

1. Maternal age marital status,

2. Occupational status

3. Educational status

4. Any surgical procedure

5. Gestational age

6. Body tattooing

7. Genital mutilation

8. History of blood transfusion

9. History of multiple sexual practices

6. Table as part of main manuscript and Supplementary table- Thank you for the comments and we have made corrections.

7. Title differences- Thank you, we edited it

Reviewer #1

Comment 1

Abstract

Methods; the authors should include the inclusion and inclusion criteria in the abstract. What were the outcome measures?

Response 1; the reviewer has made interesting points, and we made an amendments.

� All Pregnant women who were attending antenatal clinic and were volunteer during the study period were included, whereas those women who were unable to communicate due to any problem and not volunteer to give informed consent were excluded.

Comment 2; the authors wrote; 215 study participates were tested for HIV antibody, of which 10 (4.5%) were turned to be positive for HIV. 4 (1.86 %) of the study participants who were tested for HIV were also positive for HBsAg. The authors should avoid starting a sentence with figures.

Response 2; we thank the reviewer for his assessment, and we edited is as below

� Among the study participants, 91.1 % (215) were tested for HIV antibody during the ANC visit, with the positivity rate of 4.5 %. The result showed 1.86 % of the study participants who were tested for HIV were also positive for HBsAg.

Comment 3; the authors stated the Seropositivity of Hepatitis B Virus among Pregnant Women was found to be significant. Why did they say that the study is significant? How did they arrive at significant?

Response 3; we said it was significant in our conclusion, after comparing our result with the WHO established criteria 2015(2).

Comment 4; the authors should beef up the justification for the study

Response 4; we thank the reviewer for constructive comments,

Some amendments have been done, at the last paragraph of the introduction. We especially interested to quote the statement word by word, “Although there are guidelines for universal infant HBV vaccination, rates of maternal HBV infection have increased annually by 5.5% since 1998” (10).We ,hence interested to investigate the burden of Seropositivity in the specific study area, and put the path for the possible interventions if needed.

Reviewer # 2

Comment 1

In the introduction part; the authors should clearly summarize the state of research in the field by citing more recent seroprevalence studies, globally. From JAMA, WHO…

Response 1; we understand and agree with this observation, and we thank the reviewer for pointing this out. We incorporated the latest publications on the seroprevalence, among which the one published on JAMA. We also added the recent studies done globally and locally like studies done in Gambia, Ghana, Southern Ethiopia, and Northern Ethiopia, included in the introduction and discussion parts.

Comment 2; in the material and method, the sample size calculation procedure is not easy to read and understand, therefore it should be elucidated

Response 2; we apologise for the inconveniences and we hope know you will get the documents more visible

Sample was calculated by taking overall Hepatitis B infection prevalence among a cross-sectional study conducted among pregnant women in Gondar in 2008. Of 209 mothers included in the study, 5.3% 3.0% level of significance / margin of error (23). .This sample size will be estimated using the formula for calculating sample size for cross sectional study of estimation a single population proportion as described below.

n = (Zα/2)2 P (1-P)/ (d) 2

= (1.96)20.053(1-0.053)/ (0.03)2

214.3~214

Assumptions

Z =Standard deviation of the normal distribution = 1.96 (confidence level at 95%)

P = prevalence 5.3 %( a cross-sectional study was conducted among pregnant women in Gondar in 2008.

100-P = pregnant women who not exposed

d = Tolerable error / level of significance = 3.0%.

X=10 % non-respondent rate = 21.43

Sample size = n (Minimum sample size) + X (non- respondent) Sample size (N) = 214 + 22 = 236. Sample size was 236

Comment 3; Result-The results are not clearly presented, some values are missing and some values are different for the one in the tables. Overall the author should pay the attention to rephrase the results in appropriate manner. A table summarizing the sociodemographic characteristics should also be added, while the other tables could also be restructured.

Response 3; we thank the reviewer for pointing out this inconsistency. It is now corrected

Comment 4; Discussion-The authors should site the original studies from USA and India (mentioned in the discussion), and enrich the studies with more recent publications.

Response 4; we thank the reviewer for his kind comments and useful insights.

We tried to incorporate the recent publications on the specific topic, and also reviewed and incorporated the original studies done in USA and India that have mentioned in the original manuscript. In this study, the prevalence of Seropositivity for Hep B virus was found to be 5.1%, which was higher than research conducted in the United States to determine the seroprevalence of hepatitis B surface antigen in pregnant women. HBsAg prevalence among white non-Hispanics was 0.60%, black non-Hispanics 0.97%, Hispanics 0.14%, and Asians 5.79% (20) .It also much higher than another study conducted in India in 2016, which was 1.01 % (21) .In this study, most of the participants were in the second gravidity 90(41.9%) which was comparable to research conducted in the United States .

The Seropositivity rate in this study is also lower than the recent studies done in Gambia, Ghana, Southern and Northern parties of Ethiopia, which were 9.2 %, 7.7%, 7.3 % and 9.2 % respectively. (17-20)

Comment 5; since the authors mother tongue is not English, they should carefully revise the manuscript for grammatical and syntactical errors

Response 5; We admit that, and tried to correct some grammatical errors with the help of my fellow English department friends, and I hope you will get it better than the previous documents.

Attachment

Submitted filename: Rebuttal Letter.pdf

Decision Letter 1

Frank T Spradley

8 Mar 2021

PONE-D-20-36836R1

Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia ; Health facility based Cross-sectional Study

PLOS ONE

Dear Dr. Bededa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 22 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have endeavoured to revise the manuscript as recommended. They have addressed the most salient issues raised

Reviewer #2: We thank the authors for adequately studying and addressing both the Editor’s and our comments. The manuscript is now closer to meeting PLOS publication criteria, but there are still some points that can be mended.

Abstract and Introduction: there are some minor grammatical mistakes and some parentheses that are out of place, that could easily be corrected.

Material and Method: Thank you for pointing out the inclusion and exclusion criteria and for elucidating the sample size calculation. In the section 2.6.2 Independent variables, maternal age and marital status should be in different lines, as they represent two separate sociodemographic characteristics.

Results: The authors should especially pay attention at further correcting section 3.3. For example, they state “955 CI” or “95 CI” where there should be 95% CI. In the text they are referring to sharp material sharing with others, while there are no relevant data in Table 2. Concerning genital mutilation, the p-value is different in the text and in Table 2. Also, the last line from Table 2, HIV status- Option No, is missing.

Discussion: There are some parentheses here also that are misplaced.

The authors specifically state “In this study multi-partners, gravidity and

HIV status had significant association”, while earlier, in the results, they state that “Among those factors affecting the transmission of HBV infection like age, marital status, gravidity, educational level, religion, and ethnicity none has a significant association”. Since gravidity was not found to have a significant association with HBsAg status, this sentence should be corrected.

Finally, when the authors say that HIV and HBV share the same mechanisms of transmission, the should cite relevant bibliography.

When this issues are also addressed, then the manuscript will be finally acceptable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: George Eleje

Reviewer #2: Yes: Tagkou Nikoletta Maria

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 25;16(3):e0249216. doi: 10.1371/journal.pone.0249216.r004

Author response to Decision Letter 1


11 Mar 2021

I,on behalf of all authors,am really thankful to respond to your valuable and constructive comments,and really appreciate your reasonable and scientific comments! Thank you!

Attachment

Submitted filename: Letter to Reviewers on Minor revision on HBV among pre.pdf

Decision Letter 2

Frank T Spradley

15 Mar 2021

Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia ; Health facility based Cross-sectional Study

PONE-D-20-36836R2

Dear Dr. Bededa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Acceptance letter

Frank T Spradley

17 Mar 2021

PONE-D-20-36836R2

Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia; Health facility based Cross-sectional Study

Dear Dr. Bededa:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Questionnaire

    (PDF)

    S1 Table. Seroprevalence of HBsAg among pregnant women attending ANC in DURH from December to May 28, 2017.

    (PDF)

    Attachment

    Submitted filename: Rebuttal Letter.pdf

    Attachment

    Submitted filename: Letter to Reviewers on Minor revision on HBV among pre.pdf

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES